Development and Characterization of Nanoliposomal Hydroxyurea Against BT-474 Breast Cancer Cells

• Váldodahkkit: Azam Akbari (Dahkki), Azim Akbarzadeh (Dahkki), Morteza Rafiee Tehrani (Dahkki), Reza Ahangari Cohan (Dahkki), Mohsen Chiani (Dahkki), Mohammad Reza Mehrabi (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Tabriz University of Medical Sciences, 2020-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Purpose: Hydroxyurea (HU) is a well-known chemotherapy drug with several side effects which limit its clinical application. This study was conducted to improve its therapeutic efficiency against breast cancer using liposomes as FDA-approved drug carriers. Methods: PEGylated nanoliposomes-containing...